Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

Fibrogen Inc. diskutieren

Fibrogen Inc.

WKN: A12EZ0 / Symbol: FGEN / Name: FibroGen / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

0,23 €
0,44 %

FibroGen, Inc. (NASDAQ: FGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for FGEN provided by MarketBeat

Einschätzung Sell
Rendite (%) -75,48 %
Kursziel 1,83
Veränderung
Endet am 08.08.24

FibroGen, Inc. (NASDAQ: FGEN) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $2.00 price target on the stock, down previously from $4.00.
Ratings data for FGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -67,67 %
Kursziel 9,53
Veränderung
Endet am 20.02.26

FibroGen, Inc. (NASDAQ: FGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for FGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -31,01 %
Kursziel 9,16
Veränderung
Endet am 18.03.26

FibroGen, Inc. (NASDAQ: FGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for FGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -16,55 %
Kursziel 9,00
Veränderung
Endet am 13.05.26

FibroGen, Inc. (NASDAQ: FGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Ratings data for FGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 36,87
Veränderung
Endet am 07.08.26

FibroGen, Inc (NASDAQ: FGEN) had its price target raised by analysts at HC Wainwright from $10.00 to $43.00. They now have a "buy" rating on the stock.
Ratings data for FGEN provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 36,44
Veränderung
Endet am 24.09.26

FibroGen (NASDAQ:FGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
Ratings data for FGEN provided by MarketBeat